Gemcitabine has been noted to have positive effects on CD8+ cytotoxic T cell antitumor activity, possibly as a consequence of diminishing the viability of MDSCs in the tumor microenvironment,65 as well as by its abovementioned ability to enhance T cell priming. This evidence concerns the gene CD8A and neoplasm.